An official website of the United States government
Home
Name
Belantamab mafodotin-blmf
Alternate Names
Blenrep
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
NSC Number
None
Primary Site
None
Histology
Multiple myeloma
Remarks
August 5, 2020 The FDA approved belantamab mafodotin-blmf (Blenrep) for adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
On October 23, 2025, the FDA approved belantamab mafodotin-blmf (Blenrep), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.
On October 23, 2025, the FDA approved belantamab mafodotin-blmf (Blenrep), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.
Coding
This drug should be coded
